Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2506-2514

  Delobel, Pierre ^a,c   Cazabat, Michelle ^a,c   Saliou, Adrien ^a   Loiseau, Claire ^a   Coassin, Lucile ^a   Raymond, Stéphanie ^a,b,c   Requena, Mary ^a,c   Marchou, Bruno ^b,c   Massip, Patrice ^b,c   Izopet, Jacques ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Drug resistance; Env; Haart; Maraviroc; Receptors

Indexed keywords

MARAVIROC;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DATA BASE; FRANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; VIRAL TROPISM; VIRUS ENTRY; VIRUS ISOLATION; VIRUS MUTATION;

ENV; HAART; MARAVIROC; DRUG RESISTANCE; RECEPTORS;

ANTI-HIV AGENTS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; FRANCE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; TRIAZOLES;

EID: 84886289292     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt249     Document Type: Article

References (37)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
2. Dorr P,Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
3. Fatkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-2.
4. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
5. Tsamis F, Gavrilov S, Kajumo F et al. Analysis of the mechanism by which the small-molecule CCR5antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77: 5201-8.
6. Dragic T, Trkola A, Thompson DA et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000; 97: 5639-44.
7. Fatkenheuer G, Nelson M, Lazzarin A et al. Subgroupanalyses ofmaraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-55.
8. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is fromapretreatmentCXCR4-usingvirus reservoir.JVirol2006;80:4909-20.
9. Heera J, Saag M, Ive P et al. Virological correlates associated with treatment failure at week 48 in the Phase 3 study of maraviroc in treatment-naive patients. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 40LB. CROI, LLC, Alexandria, VA, USA.
10. Archer J, Braverman MS, Taillon BE et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009; 23: 1209-18.
11. Westby M, Smith-Burchnell C, Mori J et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81: 2359-71.
12. Pugach P, Marozsan AJ, Ketas TJ et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361: 212-28.
13. Tsibris AM, Sagar M, Gulick RM et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008; 82: 8210-4.
14. Berro R, Sanders RW, Lu M et al. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 2009; 5: e1000548.
15. Nolan KM, Del Prete GQ, Jordan AP et al. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J Virol 2009; 83: 3798-809.
16. Kuhmann SE, Pugach P, Kunstman KJ et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78: 2790-807.
17. Ogert RA,Wojcik L, Buontempo C et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008; 373: 387-99.
18. Ogert RA, Ba L, Hou Y et al. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol 2009; 83: 12151-63.
19. BabaM, MiyakeH, Wang X et al. Isolationandcharacterization ofhuman immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 2007; 51: 707-15.
20. Lewis M, Simpson P, Whitcomb J et al. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 871. CROI, LLC, Alexandria, VA, USA.
21. Lewis M, Simpson P, Delogne C et al. Genotypic analysis of the HIV-1 gp120 V3 loop for treatment-experienced patients enrolled into the MOTIVATE studies and who received maraviroc+ optimized background therapy. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 539. CROI, LLC, Alexandria, VA, USA.
22. Berro R, Klasse PJ, Jakobsen MR et al. V3 determinants of HIV-1 escape fromtheCCR5inhibitorsmaravirocandvicriviroc. Virology2012;427:158-65.
23. Anastassopoulou CG, Ketas TJ, Depetris RS et al. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology 2011; 413: 47-59.
24. Anastassopoulou CG, Ketas TJ, Klasse PJ et al. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci USA 2009; 106: 5318-23.
25. Ratcliff AN, Shi W, Arts EJ. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J Virol 2013; 87: 923-34.
26. Armand-Ugon M, Moncunill G, Gonzalez E et al. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. J Antimicrob Chemother 2013; 65: 417-24.
27. Seclen E, Gonzalez Mdel M, Lapaz M et al. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. J Antimicrob Chemother 2010; 65: 2502-4.
28. Soulie C, Malet I, Lambert-Niclot S et al. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. AIDS 2008; 22: 2212-4.
29. Raymond S, Delobel P, Mavigner M et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010; 47: 126-30.
30. Bjorndal A,DengH, Jansson M et al. Coreceptor usage of primaryhuman immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71: 7478-87.
31. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-96.
32. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
33. Dunn DT, Coughlin K, Cane PA. Genotypic resistance testing in routine clinical care. Curr Opin HIVAIDS 2011; 6: 251-7.
34. Pfizer Inc. Maraviroc Tablets NDA 22-128. Antiviral Drugs Advisory Committee Briefing Document, April 24, 2007. http://www.fda.gov/ ohrms/dockets/ac/07/briefing/2007-4283b1-01-pfizer.pdf (18 May 2013, date last accessed).
35. Pugach P, Ray N, Klasse PJ et al. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 2009; 387: 296-302.
36. Sallusto F, Lenig D, Forster R et al. Twosubsets ofmemoryT lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
37. Veazey RS, Mansfield KG, Tham IC et al. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 2000; 74: 11001-7.